| ELEVAR |
ELEVAR |
92%
|
Pursuant to the Elevar Agreement, Elevar was granted global development and commercialization rights for lirafugratinib. |
| PFE |
Pfizer Inc. |
92%
|
Reciprocal relationship from PFE graph: Reciprocal relationship from RLAY graph: Braftovi (encorafenib), a BRAF inhibitor indicated for use in combination with Mektovi (binimetinib), a MEK inhibitor,… |
| PFE |
Pfizer Inc. |
92%
|
Braftovi (encorafenib), a BRAF inhibitor indicated for use in combination with Mektovi (binimetinib), a MEK inhibitor, both marketed by Pfizer for the treatment of metastatic melanoma with a BRAF V60… |
| ELEVAR-AGREEMENT |
ELEVAR-AGREEMENT |
90%
|
During the three months ended March 31, 2026, the Company recognized $3.0 million of revenue from the Elevar Agreement, specifically upon receipt of certain milestone payments. |
| GENENTECH |
GENENTECH |
90%
|
Under the terms of the Genentech Agreement, we received $75.0 million in an upfront payment in 2021, as well as $45.0 million in milestone payments from Genentech as of December 31, 2024. |
| ELEVAR-THERAPEUTICS-INC |
ELEVAR-THERAPEUTICS-INC |
85%
|
ctively. Elevar Therapeutics, Inc. In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement ("Elevar Agreement"), pursuant to which Elevar w… |
| PVLA |
Palvella Therapeutics, Inc. |
72%
|
Reciprocal relationship from PVLA graph: ting approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
to the ReDiscover-2 Trial. General and Administrative Expenses General and administrative expenses were $11.0 million for the three months ended March 31, 2026 compared to $18.7 million for the three… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
to justify the transaction. Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies… |
| D-E-SHAW-RESEARCH-LLC |
D-E-SHAW-RESEARCH-LLC |
62%
|
ctively. Elevar Therapeutics, Inc. In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement ("Elevar Agreement"), pursuant to which Elevar w… |
| LICENSE-AGREEMENTS-ELEVAR-THERAPEUTICS-INC |
LICENSE-AGREEMENTS-ELEVAR-THERAPEUTICS-INC |
62%
|
data and other information disclosed in these notes related to the three months ended March 31, 2026 and 2025 are unaudited. The condensed consolidated results for the three months ended March 31, 20… |
| RELAY-THERAPEUTICS-SECURITIES-CORPORATION |
RELAY-THERAPEUTICS-SECURITIES-CORPORATION |
62%
|
including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations, and the need to obtain additio… |
| USA-LLC |
USA-LLC |
62%
|
may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our product candidates or otherwise expand more rapidly than we presently anticipat… |
